Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects aged 18 years and above, both genders.~2. Histologically or cytologically confirmed Primary Hepatocellular Carcinoma (HCC)~3. No fibrolamellar subtype HCC~4. Not eligible for any other systemic anti-neoplastic treatment approved for HCC~5. Not eligible for Transarterial chemoembolization (TACE ).~6. No more than 1 prior systemic therapy. Previous TACE or Radiofrequency ablation (RFA) that were used for HCC, are permitted.~7. Not a candidate for curative surgical resection or liver transplantation~8. Measurable disease defined by the identification at least 1 measurable lesion by MRI using RECIST criteria. Tumor in area of TACE or RFA must be enlarging post-procedure to be considered measurable disease.~9. Alpha-fetoprotein (AFP) greater than the upper limit of normal (ULN)~10. Child's Pugh classification A~11. ECOG performance status 0-1~Exclusion Criteria:~1. Patients progressing to liver failure.~2. No core biopsy within the past 7 days~3. Patients who are eligible for Transarterial Chemoembolization (TACE)~4. Patients on concurrent anti-neoplastic therapy (including interferon)~5. Patients who have received any systemic anti-neoplastic therapy not approved for the treatment of HCC.~6. Patients on concurrent steroids, other than those allowed for routine antiemetics, or inhaled steroids~7. Presence of metastasis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CT-011 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).